Sanofi India Limited and Cipla Limited have joined forces in an exclusive partnership for the distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. This collaboration means that Cipla will take charge of distributing Sanofi India’s six CNS brands, including the well-known Frisium®, which is a leading anti-epileptic medication.
While Sanofi India will retain ownership and continue to import and manufacture its complete range of CNS products, Cipla will utilize its strong marketing and sales network, along with its expertise in reaching out to various institutions and programs, to expand access to these treatments for patients in need.
This partnership is aimed at enhancing the availability and reach of Sanofi India’s CNS products across the country. By leveraging Cipla’s extensive distribution capabilities and India-wide network, more patients will have access to these vital treatments.
Mr. Rodolfo Hrosz, Managing Director, Sanofi India Limited shared “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Mr. Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited said, “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”
Sanofi India continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including Diabetes, Transplants, Rare Diseases, Consumer Healthcare and Vaccines.
Sanofi – in India for India
As Sanofi India, we are in a great place to make a difference. Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people’s lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.
Our India Charitable Access Program is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices – for 5 years in a row (since 2019), our local entities include Sanofi India Limited (SIL – listed entity) and Sanofi Healthcare India.
